Consensus Immatics N.V.

Stocks

IMTX

NL0015285941

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 01/09/2026 HKT			5-day change	1st Jan Change
9.530 ^USD	+0.85%		+9.67%	-9.24%

08-25	Immatics Announces $150 Million Underwritten Offering	MT
08-18	Immatics' Q2 Net Loss Narrows as Revenue Rises	MT

Evolution of the Average Target: Immatics N.V.

Evolution of the Target Price: Immatics N.V.

Changes in Analyst Recommendations: Immatics N.V.

d273b.ZCARMdVlcOXUzc7SVfInX_RmlK-yPqnrgmhuRd36TL8.B2YiboA6RIGSuIWQH54RMcIF8ciFVsLcxyo6COmTDdU8UklXoBADr6OloQ~d6239fcdde61d17b903808b56ede0ed0

Analysts' recommendations: Immatics N.V.

04-28	TD Cowen Initiates Immatics at Buy	MT
03-06	Deutsche Bank Lifts Price Target on Immatics to $18 From $17, Keeps Buy Rating	MT
01-07	Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says	MT
01-06	BofA Adjusts Price Target on Immatics to $17 From $14, Maintains Buy Rating	MT
11-19	Mizuho Raises Price Target on Immatics to $23 From $19, Keeps Outperform Rating	MT
18/09/25	Guggenheim Initiates Coverage on Immatics N.V With Buy Rating, $16 Price Target	MT
28/05/25	Deutsche Bank Initiates Coverage on Immatics With Buy Rating, $10 Price Target	MT
07/01/25	BofA Securities Adjusts Price Target on Immatics to $13 From $15, Maintains Buy Rating	MT
07/10/24	Piper Sandler Initiates Immatics With Overweight Rating, $19 Price Target	MT
15/05/24	Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating	MT
02/11/23	Cantor Fitzgerald Initiates Coverage on Immatics with Overweight Rating	MT
18/08/23	Mizuho Ups Price Target on Immatics to $14 From $12, Maintains Buy Rating	MT
31/03/23	Mizuho Initiates Immatics at Buy With $12 Price Target	MT
23/03/23	Chardan Adjusts Price Target on Immatics to $25 From $28, Keeps Buy Rating	MT
10/08/22	Chardan Research Adjusts Price Target on Immatics to $28 From $30, Reiterates Buy Rating	MT
03/06/22	SVB Securities Adjusts Immatics NV's Price Target to $26 from $25, Keeps Outperform Rating	MT
24/03/22	SVB Leerink Adjusts Immatics' Price Target to $25 from $32, Keeps Outperform Rating	MT
14/12/21	SVB Leerink Adjusts Immatics PT to $32 From $28, Maintains Outperform Rating	MT
15/07/21	Immatics N : SVB Leerink Adjusts Immatics NV's Price Target to $27 from $26, Keeps Outperform Rating	MT
18/03/21	Immatics N : Chardan Adjusts Immatics' Price Target to $30 From $28, Reiterates Buy Rating	MT
18/03/21	Immatics N : SVB Leerink Adjusts Immatics NV Price Target to $26 From $17, Maintains Outperform Rating	MT
20/11/20	Immatics N : BofA Securities Starts Immatics at Buy With $13 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	IMMATICS N.V.					+85.03%
	WUXI APPTEC CO., LTD.					+18.83%
	ARGENX SE					+12.23%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.45%
	INSMED INCORPORATED					+64.33%
	BIONTECH SE					+18.32%
	PHARMAESSENTIA CORPORATION					-3.81%
	GENMAB A/S					+14.38%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+24.38%
	EXELIXIS, INC.					-1.74%
	Average					+24.84%
	Weighted average by Cap.					+19.22%